DERIFENAC 7.5 - Darifenacin HBr ER Tablets for Overactive Bladder by Steris Pharma.

DERIFENAC 7.5

Darifenacin HBr ER (7.5mg)

DERIFENAC 7.5 is a specialized formulation of Darifenacin HBr Extended-Release (ER) tablets, each containing 7.5mg of Darifenacin Hydrobromide. Manufactured by Steris Pharma, DERIFENAC 7.5 is prescribed for the management of overactive bladder (OAB) symptoms in adults.

Key Features and Benefits:

1. Overactive Bladder Management: DERIFENAC 7.5 is specifically designed to treat symptoms of overactive bladder, including urinary urgency, frequency, and incontinence. It helps improve bladder control and reduces episodes of involuntary bladder contractions.

2. Extended Release Formulation: The extended-release formulation of DERIFENAC 7.5 ensures a gradual release of Darifenacin, providing sustained therapeutic effect throughout the day and night. This minimizes the frequency of dosing and enhances patient compliance.

3. Smooth Muscle Relaxation: Darifenacin, the active ingredient in DERIFENAC 7.5, acts as a selective muscarinic receptor antagonist, leading to relaxation of the detrusor muscle in the bladder. This mechanism helps decrease bladder contractions and improves bladder capacity.

4. Improved Quality of Life: By reducing OAB symptoms, DERIFENAC 7.5 contributes to an improved quality of life for patients, allowing them to engage in daily activities without the constant worry of urinary urgency and incontinence.

Dosage and Administration:

• The recommended dosage of DERIFENAC 7.5 is one tablet (7.5mg) taken orally once daily, preferably at the same time each day.
• Tablets should be swallowed whole with water and not crushed, chewed, or broken.

Safety and Precautions:

• Patients with known hypersensitivity to Darifenacin or other components of DERIFENAC 7.5 should avoid its use.
• Common side effects may include dry mouth, constipation, blurred vision, and urinary retention. Patients should report any severe or persistent adverse effects to their healthcare provider.

Conclusion:

DERIFENAC 7.5 offers effective and convenient management of overactive bladder symptoms, providing relief from urinary urgency, frequency, and incontinence. With its extended-release formulation and well-tolerated profile, DERIFENAC 7.5 is a valuable option for patients seeking relief from OAB-related challenges. Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. gynecology, Pediatrics, Dental care, and Dermatology.The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

 For further information: 

  EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

 CALL/WHATSAPP: 7877551268, 7849827488

 BUY NOW